Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The data lay this out: only 19% of firms with 200 or more workers include coverage for GLP-1 agonists when used for weight-loss in their largest health plan in 2025
They use phrases like supports satiety, helps regulate appetite, and supports healthy blood glucose after meals, paired with the standard disclaimer that the FDA has not evaluated the statements and that the product is not intended to diagnose, treat, cure, or prevent disease
This is further supported by improved outcomes in the matched cohort comparisons within the study group relative to the control group
Drug manufacturers face an uphill battle unless they can demonstrate concrete harm
US$ 25.99
US$ 23.81
US$ 21.15
US$ 23.32
US$ 28.14
US$ 24.40
